文献速递眼底病与葡萄膜炎

载脂蛋白A-I模拟肽L-4F清除老年非人灵长类Bruch膜脂质

Apolipoprotein A-I Mimetic Peptide L-4F Removes Bruch's Membrane Lipids in Aged Nonhuman Primates.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

在≥20岁食蟹猴中开展剂量递增研究,单眼玻璃体腔注射L-4F(n=7)或对照乱序肽(n=2),6次剂量25–175 μg历时6个月。L-4F注射眼Bruch膜中性脂质、酯化胆固醇及膜攻击复合物被清除且超微结构改善,对侧眼同样受累;黄斑镜下黄色病灶对应RPE脂质变性且治疗未改变。

要点

  • L-4F玻璃体腔注射可清除老年非人灵长类Bruch膜中性脂质和酯化胆固醇。
  • L-4F注射眼Bruch膜膜攻击复合物减少且超微结构改善,对侧眼同样受影响。
  • RPE脂质变性相关黄色病灶在本治疗下未见改变。

核心结论

  • 临床阶段载脂蛋白A-I模拟肽L-4F重复玻璃体腔给药可在非人灵长类模型中显著降低Bruch膜脂质并恢复超微结构。

研究设计与样本

  • 研究纳入≥20岁的食蟹猴,经彩色眼底照相和光学相干断层扫描评估后接受单眼玻璃体腔注射。
  • L-4F组n=7,对照乱序肽组n=2,6次剂量25–175 μg,历时6个月。
  • 眼组织用于Bruch膜中性脂质(油红O染色)、酯化胆固醇(filipin组织化学)、膜攻击复合物(免疫荧光)及旁黄斑厚度(透射电镜)的盲法半定量评估。

主要发现

  • 与对照注射眼相比,L-4F注射眼Bruch膜中性脂质、酯化胆固醇和膜攻击复合物被清除且超微结构改善。
  • 对侧眼也受到同等程度影响。
  • 无对应RPE隆起的点状黄色眼底病灶与RPE脂质变性(脂滴充盈)相关,该治疗未改变此病变。

临床怎么用

  • 提示玻璃体腔注射载脂蛋白A-I模拟肽可能作为清除Bruch膜脂质、干预软性玻璃膜疣前驱病变的潜在策略。
  • RPE脂质变性相关病灶可能不在此治疗靶点范围内,需另行评估。

局限性

  • 研究为非人灵长类动物模型,样本量小(L-4F组n=7、对照组n=2),结论尚未在人体验证。
  • 观察期6个月,长期疗效与安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiple evidence lines support Bruch's membrane lipid deposition as a major precursor of soft drusen and age-related macular degeneration as including a potentially treatable atherosclerosis-like progression in the subretinal pigment epithelium (RPE)-basal lamina space. We evaluated the effect of anti-inflammatory, antiatherogenic peptide L-4F on Bruch's membrane of aged nonhuman primates in a dose-escalating study. METHODS: Macaca fascicularis ≥20 years of age evaluated by color fundus photography and optical coherence tomography received monocular intravitreal injections of L-4F (n = 7) or a placebo-scrambled peptide (n = 2) in 6 doses of 25 to 175 μg over 6 months. Eyes were processed for detection and masked semiquantitative assessment of macular Bruch's membrane neutral lipid (oil red O staining), esterified cholesterol (filipin histochemistry), membrane attack complex (immunofluorescence), and paramacular thickness (transmission electron microscopy). RESULTS: Bruch's membrane neutral lipid, esterified cholesterol, and membrane attack complex were cleared and ultrastructure was improved in L-4F-injected eyes, compared to placebo-injected eyes. Fellow eyes were also affected to the same degree as the injected eyes. Punctate yellow fundus lesions without corresponding RPE elevations on optical coherence tomography correlated to RPE lipoidal degeneration (engorgement with lipid droplets), which was unchanged by this treatment. CONCLUSIONS: Clinical-stage apolipoprotein A-I mimetic peptide L-4F, delivered intravitreally in repeated doses, produced a substantial pharmacologic reduction of Bruch's membrane lipid and restoration of ultrastructure in a nonhuman primate model that exhibits an important precursor of soft drusen, if not soft drusen themselves.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Rudolf M, Curcio CA, Schlötzer-Schrehardt U, et al. Apolipoprotein A-I Mimetic Peptide L-4F Removes Bruch's Membrane Lipids in Aged Nonhuman Primates. Invest Ophthalmol Vis Sci. 2019. PMID: 30707219. doi:10.1167/iovs.18-25786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。